7:07 PM
 | 
Apr 09, 2007
 |  BC Extra  |  Top Story

Safety signal in Entereg Phase III

Adolor (ADLR) and GlaxoSmithKline (LSE:GSK; GSK) said preliminary 12-month data from the double-blind Phase III Study 767905/014 for chronic opioid-induced bowel dysfunction (OBD) showed that patients taking 0.5 mg of Entereg twice daily had an increase in cardiovascular and neoplasm serious adverse events vs. placebo. In the...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >